Professor David Dearnaley

Professor of Uro-Oncology
MA
MD
FRCR
FRCP

Biography

Professor David Dearnaley joined the Academic Unit of Radiotherapy at The Royal Marsden and The Institute of Cancer Research (ICR) as Bob Champion Senior Lecturer and Honorary Consultant in 1987. He subsequently became Reader in Prostate Cancer Studies in 1999 and Professor of Uro-Oncology in 2003.

He was Head of The Royal Marsden Urology Unit from 1994 to 2006 and is currently Chairman of The Royal Marsden and ICR Committee for Clinical Research, and the SW Thames Cancer Network Urology Tumour Working Group.

He is the Urology Lead for The Royal Marsden / ICR Biomedical Research Centre. He was appointed an NIHR Senior Investigator in 2008 and is a member of the NHS HTA Clinical Evaluation and Trials Board. He has previously chaired both the MRC and NCRI Prostate Study Groups, as well as the MRC Radiotherapy Clinical Trials Group.

Principal areas of research have been in the development of conformal and, subsequently, intensity modulated radiotherapy (IMRT) treatments for prostate cancer. He has led phase III randomised trials to establish these in clinical practice and is the chief investigator leading a multicentre trial of intensity modulated radiotherapy using hypofractionated schedules; known as CHHiP, this is the largest academic treatment trial undertaken in prostate cancer. The results of its conformal and dose escalation studies in prostate cancer have been incorporated in NICE guidance. He also has major interests in the treatment of castrate-resistant prostate cancer and bone metastases in prostate cancer.

Clinical teams

Urology Unit